NCT01702350View on ClinicalTrials.gov

A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 21, 2011

Primary Completion Date

December 8, 2011

Study Completion Date

December 8, 2011

Conditions
Community-acquired Infection
Interventions
DRUG

GSK2251052

Oral formulation of an an antibacterial

Trial Locations (1)

5000

GSK Investigational Site, Adelaide

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01702350 - A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study | Biotech Hunter | Biotech Hunter